Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers

摘要: Iodine seed implant brachytherapy is indicated for low risk and selected favorable intermediate prostate cancers. A percentage of positive biopsies > 50% usually considered as a contra-indication, the tumor location could also influence treatment efficacy. We studied association biopsy cores, location, with progression-free survival. Among 382 patients treated at our center by permanent iodine localized cancer between 2006 2013, 282 had accessible detailed pathology reports, minimum follow-up 6 months, were included. Progression was defined biochemical, local, nodal, or distant metastatic relapse. on (base, midgland or apex prostate) well potential confounders (pre-treatment PSA, stage, Gleason score, group according to D’Amico’s classification modified Zumsteg, adjunction androgen deprivation therapy, dosimetric data). Most (197; 69.9%) risk, 67 (23.8%) 16 (5.7%) an unfavorable 1 (0.3%) high-risk cancer. An involvement found 131 (46,5%), midgland for 149 (52,8%), base 145 (51,4%). The median cores 17% [3–75%]. 64 months [12–140]. Twenty (7%) progressed: 4 progressions (20%) biochemical only, 7 (35%) prostatic seminal, 6 (30%) 3 (15%) metastatic. time failure 39.5 months [9–108]. There more scores ≥7 among who progressed (40% vs 19%; p = 0.042). None covariates (including cores), significantly associated showed trend towards (p = 0.055). Brachytherapy efficient (5-year control rate 93%) carefully classical criteria. not score ≥ 7 frequent in case progression.